MedTrace Logo

KM3D Multicenter Cancer Consortium: Predicting Patient Response Using 3D Cell Culture Models

NCT05338073 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2023-04-24

No results posted yet for this study

Summary

This study will assess the ability of the Known Medicine platform to predict the efficacy of certain cancer drug treatments and to validate that tumor organoid drug sensitivity is representative of patient treatment outcomes.

Conditions

  • Cancer
  • Predictive Cancer Model
  • Effects of Chemotherapy

Interventions

DIAGNOSTIC_TEST

Known 3Dx Test

Cancer tissue is cultured and treated with a panel of FDA approved chemotherapy and targeted therapies at a range of doses. Cell growth and phenotypes are measured to determine which treatment or treatment combinations would yield the best results for a patient. Test results are compared to actual patient outcomes collected at 3, 6, 9, and 12 months post tissue collection to determine the predictive power of the Known 3Dx Test

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    collaborator OTHER

  • Duke Cancer Institute

    collaborator OTHER

  • Mayo Clinic

    collaborator OTHER

  • Known Medicine, Inc.

    lead INDUSTRY

Principal Investigators

  • Andrea Mazzocchi, PhD · Known Medicine, Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-12
Primary Completion
2025-01-31
Completion
2026-01-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05338073 on ClinicalTrials.gov